Correction to : Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines
| Errataetall: |
ErratumFor: Hepatol Int. 2021 Dec;15(6):1421-1430. - PMID 34741723 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Hepatology international - (2024) vom: 22. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Teng, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 22.01.2024 published: Print-Electronic ErratumFor: Hepatol Int. 2021 Dec;15(6):1421-1430. - PMID 34741723 Citation Status Publisher |
|---|
| doi: |
10.1007/s12072-023-10634-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367428644 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367428644 | ||
| 003 | DE-627 | ||
| 005 | 20240122232241.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240122s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12072-023-10634-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1267.xml |
| 035 | |a (DE-627)NLM367428644 | ||
| 035 | |a (NLM)38252366 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Teng, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Correction to |b Risk scores to predict HCC and the benefits of antiviral therapy for CHB patients in gray zone of treatment guidelines |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 22.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumFor: Hepatol Int. 2021 Dec;15(6):1421-1430. - PMID 34741723 | ||
| 500 | |a Citation Status Publisher | ||
| 650 | 4 | |a Published Erratum | |
| 700 | 1 | |a Chang, Ting-Tsung |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hwai-I |e verfasserin |4 aut | |
| 700 | 1 | |a Peng, Cheng-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Chien-Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Su, Tung-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Tsung-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Ming-Lung |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Hung-Chih |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Jaw-Ching |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Hepatology international |d 2007 |g (2024) vom: 22. Jan. |w (DE-627)NLM190585528 |x 1936-0541 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:22 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12072-023-10634-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 22 |c 01 | ||